Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts

Clinical Cancer Research

Volumn 7, Issue 2, 2001, Pages 358-366

  Kirstein, M N ^a   Houghton, P J ^a   Cheshire, P J ^a   Richmond, L B ^a   Smith, A K ^a   Hanna, S K ^a   Stewart, C F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; LACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHILDHOOD CANCER; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LACTONES; MICE; MICE, INBRED CBA; NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0035127478     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Mechanism of action of eukaryotic DNA topoisomerase 1 and drugs targeted to the enzyme
2. DNA topoisomerases
3. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts
4. A Phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin
5. A Phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer
6. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma
7. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: A frequency-domain fluorescence spectroscopic study
8. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts
9. The direct translation of a protracted irinotecan schedule from a xenograft model to a Phase I trial in children
10. Pharmacokinetically guided dose adjustment reduces variability in topotecan (TPT) systemic exposure in children with solid tumors
11. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models
12. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts
13. Growth and characterization of childhood rhubdomyosarcoma as xenografts
14. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors
15. Efficacy of topoisomerase 1 inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
16. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography
17. Noncompartment analysis based on statistical moment theory
18. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins
19. Phase 1 and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors
20. Phase 1 clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)
21. Phase 1 trial of 9-aminocamptothecin in children with refractory solid tumors: A Pediatric Oncology Group study
22. Phase 1 and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients
23. Phase 1 and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia
24. Phase 1 pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks
25. Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva